INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.

Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.

Key topics discussed include:
•⁠  ⁠Overview of the INAVO120 study and its significance
•⁠  ⁠The unique patient population targeted in the study
•⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS)
•⁠  ⁠Side effects and management strategies for patients
•⁠  ⁠The importance of genetic testing in treatment decisions

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com